CTP-543 Clinical Trial Initiated

This phase 2 for Alopecia Areata will have a primary endpoint with the number of responders achieving at least 50% improvement in SALT score at 24 weeks.

Estimated Enrollment: 100
Anticipated Study Start Date:	May 2017
Estimated Study Completion Date:	July 2018
Estimated Primary Completion Date:	March 2018 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: CTP-543, 4 mg Oral tablet, dosed twice-daily	Drug: CTP-543 tablets
Experimental: CTP-543, 8 mg Oral tablet, dosed twice-daily	Drug: CTP-543 tablets
Experimental: CTP-543, 12 mg Oral tablet, dosed twice-daily	Drug: CTP-543 tablets
Experimental: CTP-543, 16 mg Oral tablet, dosed twice-daily	Drug: CTP-543 tablets
Experimental: Placebo Oral tablet, dosed twice-daily	Drug: Placebo tablets

Detailed Description:

This is a double-blind, randomized, placebo-controlled, parallel dose-comparison, multi-center study of CTP-543. Subjects will be randomized to either an active dose of CTP-543 or placebo for an initial 24-week efficacy period. A 28-week dose-adjustment period will follow where patients tolerating treatment may adjust dose at Week 24 as needed, and placebo patients will be switched to active treatment.

 

Below is a daily chart of Concert Pharmaceuticals. The stock has been basing since the big move higher on March 6, when the company announced the sale of CTP-656 to Vertex. Thank you for reading.